Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioInvent Treats First Patient In Phase I Study Of BI-505
BioInvent International (BioInvent) has treated first patient in an open, dose-escalation Phase I study of antibody BI-505 for patients with advanced multiple myeloma. The Phase I study will
BioInvent International (BioInvent) has treated first patient in an open, dose-escalation Phase I study of antibody BI-505 for patients with advanced multiple myeloma. The Phase I study will
Immunodiagnostic Systems (IDS) has reported that Italy-based Technogenetics has signed a five year distribution agreement with A Menarini Diagnostics (Menarini) covering Europe for an automated test system, the
Ranbaxy Labroratories (Ranbaxy) has launched a new chemical entity (NCE), Lulifin (Luliconazole), in the Indian dermatology market following a strategic in-licencing agreement with Summit Pharmaceuticals International (SPI) that
Adventrx Pharmaceuticals (Adventrx) has submitted a new drug application (NDA) to the FDA for its product candidate ANX-530 (vinorelbine injectable emulsion). The company is seeking approval of ANX-530
The FDA has accepted for review and granted priority review designation for the InterMune’s New Drug Application (NDA) for Pirfenidone, for the treatment of patients with idiopathic pulmonary
Cardiogenesis has submitted an IDE (Investigational Device Exemption) to the FDA to initiate a safety and feasibility trial for its Phoenix System in patients with refractory angina. The
Cepheid has been granted Emergency Use Authorization (EUA) from the FDA for its ‘Xpert’ Flu A Panel test. The test, which runs on GeneXpert System, identifies the 2009
Hennepin County Medical Center (HCMC) has reported that a five-year study of patients with severe traumatic brain injury. The study conducted at HCMC in Minneapolis shows significant benefit
NeoPharm has filed an investigational new drug application (IND) with the FDA for IL13-PE38QQR (IL13-PE), for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The company said that the
Dr. Reddy’s Laboratories and Rheoscience, a subsidiary of Nordic Bioscience, have reported the headline results from the first phase III study for their investigational agent, Balaglitazone. Reportedly, the